Program overview
Context
Indication: Urothelial Carcinoma
Mechanism: Unknown
Modality: Unknown
Sponsor: Incyte Corporation
Registry Stop Signal
retifanlimab
retifanlimab is flagged as registry stop signal because public records show a registry stop signal. This is a public-data monitoring signal, not a conclusion about clinical failure, regulatory noncompliance, or sponsor intent.
Scores
Risk-signal summary
Registry: 5/5
Timeline: 0/5
Recruitment burden: 1/5
Results availability: 0/5
Program risk: 3/5
Evidence
Public links
https://clinicaltrials.gov/study/NCT04586244 | https://clinicaltrials.gov/study/NCT03597295
Linked trials
Trial-level signal details
| Trial | Status | Timeline | Results | Burden |
|---|---|---|---|---|
| NCT04586244 | Registry Stop Signal (TERMINATED) | None | Low Signal | strict_eligibility_signal |
| NCT03597295 | Low Signal (COMPLETED) | None | Low Signal | strict_eligibility_signal |